相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro
Gabriele D. Maurer et al.
NEURO-ONCOLOGY (2009)
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
F. M. Iwamoto et al.
NEUROLOGY (2009)
Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric brain tumor consortium study PBTC-012
Tobey J. MacDonald et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
Kathleen R. Lamborn et al.
NEURO-ONCOLOGY (2008)
New molecular targets in malignant gliomas
John F. de Groot et al.
CURRENT OPINION IN NEUROLOGY (2007)
A phase I trial of sorafenib (BAY 43-9006) for patients with recurrent or progressive malignant glioma (NABTT 0401)
L. B. Nabors et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma
L. Burt Nabors et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours
FALM Eskens et al.
EUROPEAN JOURNAL OF CANCER (2003)
Human malignant glioma therapy using anti-alpha(v)beta(3) integrin agents
S Chatterjee et al.
JOURNAL OF NEURO-ONCOLOGY (2000)
分享论文
